In a recent interview with Life Science Knowledge Hub at BIO 2024, Daniel Spurgin, Director of Strategic Partnerships at ReciBioPharm, emphasised the need for flexibility, transparency and cutting-edge solutions in RNA manufacturing. According to Chief Scientific Officer, Aaron Cowley, ReciBioPharm is leading this charge by developing an AI-driven, continuous manufacturing platform that promises to produce mRNA, saRNA, and circular RNA faster and at a lower cost.
- Күн бұрын
Reimagining the RNA manufacturing space: An interview with ReciBioPharm’s leaders
- Рет қаралды 163
Пікірлер